Fortitude Advisory Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,713
Closed -$204K 212
2024
Q3
$204K Buy
1,713
+230
+16% +$30.7K 0.13% 189
2024
Q2
$212K Buy
+1,483
New +$197K 0.13% 166
2022
Q2
Sell
-672
Closed -$37K 915
2022
Q1
$37K Hold
672
0.02% 635
2021
Q4
$38K Buy
+672
New +$36.4K 0.02% 630

Other funds holding NVO

Fortitude Advisory Group's NVO Position: Q4 2024 in Review

Fortitude Advisory Group sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 1,713 shares — an estimated $204K sold.

Fortitude Advisory Group first reported a position in NVO in Q4 2021 and held it in 4 quarters. The position peaked at $212K in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Fortitude Advisory Group reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Fortitude Advisory Group sold 1,713 Novo Nordisk shares in Q4 2024, an estimated $204K.
  • Fortitude Advisory Group first reported a position in Novo Nordisk in Q4 2021 and held it in 4 quarters.
  • Fortitude Advisory Group's Novo Nordisk position peaked at $212K in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Fortitude Advisory Group's 13F filing for Q4 2024, filed 22 Jan 2025.